文献速递重症综合管理与镇静镇痛心脑血管急症

右美托咪定改变大鼠小胶质细胞体外炎症表型

Dexmedetomidine Alters the Inflammatory Profile of Rat Microglia In Vitro.
PubMed 文献 · Neurocrit Care · 2022-11-23
一句话结论体外实验中右美托咪定降低LPS刺激小胶质细胞的TNFα及LPS/Poly I:C刺激的IL-10,并降低DAMP刺激的6-磷酸果糖激酶活性。

该研究从Sprague-Dawley大鼠分离原代小胶质细胞并培养,用脂多糖(LPS)、聚肌胞苷酸(Poly I:C)及来自先前接受控制性皮质撞击伤大鼠的创伤性脑损伤损伤相关分子模式(DAMP)激活小胶质细胞,随后给予右美托咪定(DEX)处理。24小时收集细胞上清和细胞,用酶联免疫吸附试验检测TNFα和IL-10,检测6-磷酸果糖激酶活性,并用流式细胞术分析免疫表型。结果显示DEX降低LPS刺激小胶质细胞的TNFα表达(平均差121.5±15.96 pg/mL,p<0.0001),整体降低IL-10表达(平均差39.33±14.50 pg/mL,p<0.0001),并降低LPS刺激(平均差74.93±12.50 pg/mL,p=0.0039)和Poly I:C刺激(平均差23.27±6.405 pg/mL,p=0.0221)小胶质细胞的IL-10表达;在DAMP刺激小胶质细胞中降低6-磷酸果糖激酶活性(平均差18.79±6.508 units/mL,p=0.0421)。作者认为DEX可能改变小胶质细胞的神经炎症反应,并可能影响神经损伤进展。

要点

  • 体外大鼠原代小胶质细胞中,DEX降低LPS刺激的TNFα表达(平均差121.5±15.96 pg/mL,p<0.0001)。
  • DEX整体降低小胶质细胞IL-10表达(平均差39.33±14.50 pg/mL,p<0.0001)。
  • DEX降低LPS刺激(平均差74.93±12.50 pg/mL,p=0.0039)和Poly I:C刺激(平均差23.27±6.405 pg/mL,p=0.0221)小胶质细胞的IL-10表达。
  • DAMP刺激小胶质细胞中,DEX降低6-磷酸果糖激酶活性(平均差18.79±6.508 units/mL,p=0.0421)。
  • 不同炎症刺激和DEX处理后小胶质细胞免疫表型出现不同程度改变。

适用人群与场景

  • 体外培养的Sprague-Dawley大鼠原代小胶质细胞。

研究设计与关键结果

  • 研究类型为体外细胞实验;从Sprague-Dawley大鼠分离原代小胶质细胞并培养,用LPS、Poly I:C及来自先前接受控制性皮质撞击伤大鼠的创伤性脑损伤DAMP激活小胶质细胞,随后给予DEX处理。
  • 处理24小时后收集细胞上清和细胞,用酶联免疫吸附试验检测TNFα和IL-10,检测6-磷酸果糖激酶活性,并用流式细胞术分析免疫表型。
  • LPS处理培养中,DEX降低小胶质细胞TNFα表达(平均差=121.5±15.96 pg/mL;p<0.0001)。
  • 总体上,DEX处理培养的IL-10表达低于未处理培养(平均差=39.33±14.50 pg/mL,p<0.0001)。
  • DEX降低LPS刺激小胶质细胞的IL-10表达(平均差=74.93±12.50 pg/mL,p=0.0039)和Poly I:C刺激小胶质细胞的IL-10表达(平均差=23.27±6.405 pg/mL,p=0.0221)。
  • DAMP刺激小胶质细胞中,DEX降低6-磷酸果糖激酶活性(平均差=18.79±6.508 units/mL;p=0.0421)。
  • 不同炎症刺激和DEX处理后,小胶质细胞免疫表型出现不同程度改变。

证据类型、等级与局限

  • 证据类型:体外细胞实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,DEX可能改变小胶质细胞的神经炎症反应;通过改变小胶质细胞表型,DEX可能影响神经损伤的进展。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Microglia are a primary mediator of the neuroinflammatory response to neurologic injury, such as that in traumatic brain injury. Their response includes changes to their cytokine expression, metabolic profile, and immunophenotype. Dexmedetomidine (DEX) is an α2 adrenergic agonist used as a sedative in critically ill patients, such as those with traumatic brain injury. Given its pharmacologic properties, DEX may alter the phenotype of inflammatory microglia.

METHODS: Primary microglia were isolated from Sprague-Dawley rats and cultured. Microglia were activated using multiple mediators: lipopolysaccharide (LPS), polyinosinic-polycytidylic acid (Poly I:C), and traumatic brain injury damage-associated molecular patterns (DAMP) from a rat that sustained a prior controlled cortical impact injury. After activation, cultures were treated with DEX. At the 24-h interval, the cell supernatant and cells were collected for the following studies: cytokine expression (tumor necrosis factor-α [TNFα], interleukin-10 [IL-10]) via enzyme-linked immunosorbent assay, 6-phosphofructokinase enzyme activity assay, and immunophenotype profiling with flow cytometry. Cytokine expression and metabolic enzyme activity data were analyzed using two-way analysis of variance. Cell surface marker expression was analyzed using FlowJo software.

RESULTS: In LPS-treated cultures, DEX treatment decreased the expression of TNFα from microglia (mean difference = 121.5 ± 15.96 pg/mL; p < 0.0001). Overall, DEX-treated cultures had a lower expression of IL-10 than nontreated cultures (mean difference = 39.33 ± 14.50 pg/mL, p < 0.0001). DEX decreased IL-10 expression in LPS-stimulated microglia (mean difference = 74.93 ± 12.50 pg/mL, p = 0.0039) and Poly I:C-stimulated microglia (mean difference = 23.27 ± 6.405 pg/mL, p = 0.0221). In DAMP-stimulated microglia, DEX decreased the activity of 6-phosphofructokinase (mean difference = 18.79 ± 6.508 units/mL; p = 0.0421). The microglial immunophenotype was altered to varying degrees with different inflammatory stimuli and DEX treatment.

CONCLUSIONS: DEX may alter the neuroinflammatory response of microglia. By altering the microglial profile, DEX may affect the progression of neurologic injury.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Scott MC, Haase CM, Olson SD, et al. Dexmedetomidine Alters the Inflammatory Profile of Rat Microglia In Vitro. Neurocrit Care. 2022. PMID: 36418766. doi:10.1007/s12028-022-01638-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。